olopatadine-hydrochloride and Uveitis--Anterior

Ophthalmic disorders are highly prevalent in the United States, with approximately 3.5 million individuals aged at least 40 either blind or having impaired vision. This article reviews the current leading agents and pipeline therapies for the treatment of anterior ocular inflammatory disease (AOID).. There has been great progress in the understanding of ocular pathophysiology in recent years. Although current treatments for AOID are effective and well tolerated in many patients, a continued demand persists for more efficacious alternatives to the limited modalities available to clinicians.. Several promising modalities for AOID, particularly for allergic conjunctivitis, immune treatments for uveitis and dry eye syndrome are in late-stage development that could offer optimal treatment paradigm once available in the clinic.

Topics: Anti-Infective Agents; Antibodies, Monoclonal; Chemokine CCL11; Clinical Trials as Topic; Conjunctivitis, Allergic; Cyclosporine; Dibenzoxepins; Dry Eye Syndromes; Fluoroquinolones; Histamine H1 Antagonists; Humans; Immunotherapy; Levofloxacin; Moxifloxacin; Olopatadine Hydrochloride; Uveitis, Anterior